Treatment of irritable bowel syndromeBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7489.429 (Published 24 February 2005) Cite this as: BMJ 2005;330:429
- Michael J G Farthing, professor of medicine (email@example.com)
- St George's Hospital Medical School, London SW17 0RE
Strategies involve single receptor blockade and non-pharmacological interventions
Irritable bowel syndrome is characterised by diverse symptoms including abdominal pain, altered bowel function (increased bowel frequency, constipation), bloating, abdominal distension, the sensation of incomplete evacuation, and the increased passage of mucus.w1 No unifying hypothesis explains all these symptoms, and no single agent will alleviate all components of the symptom complex. The currently favoured model to explain the symptoms includes central and end organ components. These may be combined into an integrated hypothesis that incorporates psychological factors (stress, distress, affective disorder) and dysfunction of the gut (disorders of motility, visceral hypersensitivity).1 Current standard drug treatment generally entails a symptom directed approach with drugs aimed at pain, constipation, and diarrhoea.2 Development of new drugs has focused mainly on agents that modify the effects of 5-hydroxytryptamine (5-HT) in the gut. Alternatives to this single receptor approach exist, although not all patients respond to educational and psychological interventions, and treatment with drugs will remain an option …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.